Kestra Medical Technologies Reports Strong Q3 FY26 Results with 63% Revenue Growth and Raised FY26 Guidance
KMTS sits 60% above its 52-week low of $13.25.
Summary
Kestra Medical Technologies reported strong third-quarter fiscal 2026 financial results, featuring significant revenue growth, expanded gross margins, and an upward revision of its full-year guidance.
Key Events · Earnings and Guidance · KMTS
-
Strong Q3 Revenue Growth
Reported revenue of $24.6 million for Q3 FY26, marking a 63% increase compared to the prior year period, driven by higher market share and WCD market expansion.
-
Expanded Gross Margin
Gross margin expanded significantly to 52.6% in Q3 FY26, up from 43.4% in the prior year period, attributed to volume leverage and cost improvement programs.
-
Raised FY26 Revenue Guidance
Increased fiscal year 2026 revenue guidance to $93 million, representing 55% growth over FY25, up from previous guidance of $91 million and initial guidance of $85 million.
-
Fortified Balance Sheet
Ended the quarter with $291 million in cash and cash equivalents, which includes net proceeds from an underwritten public offering of 6.9 million common shares that closed on December 4, 2025.
Analysis · KMTS · Industrial Applications And Services
Kestra Medical Technologies delivered a robust third quarter, showcasing significant operational improvements and strong market penetration. The substantial 63% year-over-year revenue growth, coupled with a notable expansion in gross margin to over 52%, indicates effective execution and improved profitability. The decision to raise full-year revenue guidance for FY26 further reinforces management's confidence in continued momentum. While the company still reports a net loss, these positive financial and operational metrics are critical for a growth-stage medical device company, demonstrating progress towards category leadership and a fortified balance sheet.
At the time of this filing, KMTS was trading at $21.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $13.25 to $30.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.